• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Summit Corporation plc - Product Pipeline Review - Q4 2010 Product Image

Summit Corporation plc - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • 35 pages
  • Global Markets Direct

Summit Corporation plc – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Summit Corporation plc - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Summit Corporation plc - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Summit Corporation plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination READ MORE >



List of Tables
List of Figures
Summit Corporation plc Snapshot
Summit Corporation plc Overview
Key Information
Key Facts
Summit Corporation plc – Research and Development Overview
Key Therapeutic Areas
Summit Corporation plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Summit Corporation plc – Pipeline Products Glance
Summit Corporation plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Summit Corporation plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Summit Corporation plc – Drug Profiles
SMT D001
Product Description
Mechanism of Action
R&D Progress
SMT D002
Product Description
Mechanism of Action
R&D Progress
SMT 14224
Product Description
Mechanism of Action
R&D Progress
SMT C2100
Product Description
Mechanism of Action
R&D Progress
SMT D003
Product Description
Mechanism of Action
R&D Progress
SMT D004
Product Description
Mechanism of Action
R&D Progress
Antiviral Program
Product Description
Mechanism of Action
R&D Progress
Drug for Tuberculosis
Product Description
Mechanism of Action
R&D Progress
Hepatatis C Program
Product Description
Mechanism of Action
R&D Progress
SMT 19969
Product Description
Mechanism of Action
R&D Progress
Summit Corporation plc – Pipeline Analysis
Summit Corporation plc – Pipeline Products by Therapeutic Class
Summit Corporation plc Pipeline Products By Target
Summit Corporation plc – Pipeline Products by Route of Administration
Summit Corporation plc – Recent Pipeline Updates
Summit Corporation plc – Locations And Subsidiaries
Head Office
Recent Developments
Dec 11, 2009: Summit plc., awwarded 2.2million pounds from the Wellcome trust.
Dec 11, 2009: Summit plc., awwarded 2.2million pounds from the Wellcome trust.
Apr 15, 2008: Summit Plc Announces A Positive Phase I Clinical Trial Of SMT D002
Apr 15, 2008: Summit Plc Announces A Positive Phase I Clinical Trial Of SMT D002
Jan 16, 2008: Summit Plc’s Lead Drug Candidate, SMT D001, Enters Phase II Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS